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Abstract
Gene expression profiling using microarray technologies provides a powerful approach to
understand complex biological systems and the pathogenesis of diseases. In the field of liver
cancer research, a number of genome-wide profiling studies have been published. These studies
have provided gene sets, that is, signature, which could classify tumors and predict clinical
outcomes such as survival, recurrence, and metastasis. More recently, the application of genomic
profiling has been extended to identify molecular targets, pathways, and the cellular origins of the
tumors. Systemic and integrative analyses of multiple data sets and emerging new technologies
also accelerate the progress of the cancer genomic studies. Here, we review the genomic
signatures identified from the genomic profiling studies of hepatocellular carcinoma (HCC), and
categorize and characterize them into prediction, phenotype, function, and molecular target
signatures according to their utilities and properties. Our classification of the signatures would be
helpful to understand and design studies with extended application of genomic profiles.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancers with dismal clinical
outcome accounting for the third cause of cancer-related death in the world [1], and its
incidence has continued to increase in the United States and Western Europe [2]. A variety
of etiological and risk factors including hepatitis virus, dietary exposure of aflatoxin B1,
alcohol, diabetes, or parasites have associated with the development of HCC. Moreover,
multi-step processes including genetic and epigenetic alterations are thought to be
accumulated during progression of HCC [3,4]. Such complexity of the pathophysiology
leads to a daunting heterogeneity of the tumors precluding unveiling disease mechanism.
In the last decade, numerous genome-wide profiling studies have been performed to
delineate the complexity of the cancers. Based on gene expression patterns, heterogeneous
HCC has been classified into homogeneous tumors with correlation of clinical outcomes.
Molecular-based subgrouping of patients allowed the development of new targeted therapies
[5,6]. This success could be accomplished by substantial progress on data analysis. Using
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gene set (i.e., signature)-based rather than single gene-based approach, data normalization,
clustering, classification, and validation workflows are now becoming standardized [7–9].
Those developments of analysis strategies and tools have been accelerated by publicly open
statistical computing resources such as bioconductor (http://www.bioconductor.-org), gene
set enrichment analysis (GSEA) [10], genetic network analysis, and other analogous
approaches.
More recently, research interest has moved toward identifying molecular determinants of
disease pathogenesis and novel therapeutic targets. For this purpose, systematic and
integrative analyses using multiple and multi-level data resources are thought as a state-of-
art strategy to identify pivotal aberrations of genetic events or signaling pathways [11].
Accordingly, the study design including analytical strategy and reporting might be different
according to the study purposes. With this reason, the gene sets identified by genome-wide
profiling studies may have different biological meanings and usage.
Here, we categorized the previously identified gene signatures from gene expression
profiling studies of liver cancer into four signature classes of prediction, phenotype,
function, and molecular targets (Table 1), and discuss their distinct properties in study
design, analysis, and validation strategies.
CLASSIFICATION OF SIGNATURES
Prediction Signature
The majority of the gene signatures in previous studies are the prediction signature which
predicts clinical outcomes. It includes the signatures generated from gene expression [12–
18], microRNA [19,20], DNA copy numbers [21], and epigenetic regulation [22]. The gene
signatures are usually developed and trained by the clinical information (e.g., survival,
recurrence, or metastasis) to be predicted.
Major concern for the prediction signatures is its clinical applicability. For clinical use, the
prediction signatures should be validated in a concrete manner. Because the predictability of
the signatures could be affected by many confounding factors including experimental
conditions (e.g., sample preparation and hybridization conditions) or population
characteristics (e.g., postoperative treatment, patient’s health, and etiological differences),
rigorous validation with appropriate sample size is required. External validation with
independent data sets is also indispensable. Simon and coworkers have suggested helpful
guidelines for study design, analysis, and validation methods for the development of
predictors [23,24]. In general, the prediction signatures do not necessarily have functional
roles [25], because they merely reflect the general condition of liver functions or host
responses without causal relations. Therefore, the prediction signature genes may not
appropriate candidates for therapeutic targets.
There are several issues to be resolved for the clinical use of the prediction signatures.
Cross-platform difference of microarray is thought to be one of major obstacle for the
clinical use of microarrays. Although the Microarray Quality Control (MAQC) project
launched by US Food and Drug Administration (FDA) has addressed the technical
reproducibility of microarray data across different sites and platforms [26], many of
microarray studies generated only a small number of overlapping genes [24,27]. This
discrepant result might be derived from the use of different platforms, probe sets, data
normalization, and processing as well as differences in the study populations [28]. To
resolve this issue, we have shown cross-platform consistency and robustness of tumor
recurrence predictors by comparing two independent data sets [17]. Such validation by
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cross-platform comparison would be a strong evidence for the robustness of the clinical
utility of prediction signatures.
Sample preparation is also one of critical drawback for the clinical use of microarray,
because handling of the RNA samples from frozen tissues is not easy in clinical setting.
Recently, Hoshida et al. [18] have shown the clinical utility of RNAs prepared from
formalin fixed, paraffin-embedded (FFPE) tissues for the prediction of prognostic outcomes
using a cDNA-mediated annealing selection extension and ligation (DASL) assay. This
study has brought the microarray technology one step closer to clinical use, because the
FFPE samples can be easily assessed in clinic [29]. They showed prognostic significance of
the prediction signature generated from nontumoral tissues, but failed to show prognostic
significance of the signatures from tumoral tissues. This finding is discrepant to the previous
studies [12–14,16,17] which have consistently demonstrated the prognostic values of the
signatures from tumoral tissue, therefore, further elaboration might be required [30].
Phenotype Signature
While the prediction signatures are generally obtained from the parameters to be predicted,
the phenotype signatures represent distinct class phenotype regardless of the prediction
parameters. For example, clinical and pathological features such as tumor grade [31],
clinical stage [32], etiology (e.g., HBV or HCV) [33], drug responses, or the presence of
certain biomarkers can be used for sample classification labels. Also, genetic events such as
gene mutations or DNA copy number variations can be used as phenotype classifiers [34–
36].
Remarkably, recent identification of the expression traits of tumor cellular origins could
represent distinct tumor phenotypes. The identification of hepatoblast-like signature has
stratified a novel HCC subtype harboring hepatic progenitor cell-like trait [37]. This study
has demonstrated a strong correlation of the cell-type traits with patients’ prognosis,
suggesting that the cellular origin of the tumors is a critical determinant for cancer
progression. EpCam [38] and CK19 [39] were also identified as classifier for progenitor-
derived HCC. Similarly, the hepato-blastoma-derived signature has been identified from
childhood hepatoblastomas predicting clinical outcome [40]. However, the progenitors
might be heterogeneous according to their differentiation status. With this concern, we have
recently identified a cholangiocarcinoma (CC)-like gene expression trait (i.e., CC signature)
representing a biliary differentiation trait in HCC [41]. In this study, we have shown
functional and prognostic implications of the CC signature in HCC progression, suggesting
distinct property of differentiation trait compared with those of stem-like trait. Taken these
findings together, we could suggest that the different cellular origins from distinct
developmental stage of primitive hepatic progenitor cells to differentiated hepatic or biliary
precursors can give rise to heterogeneous HCC phenotypes (Figure 1).
As like the prediction signature, the phenotype signatures have correlated with clinical
outcomes (Table 1) [37,40,41]. However, these phenotype signatures do not necessarily
have strong prediction power for clinical outcomes, because their primary goal is to address
the functional characteristics of a certain tumor subtype. For example, the HCC class
identified by a certain genetic phenotypes such as 17q amplification was not strongly
associated with patient’s survival, but functionally liked to drug sensitivity to rapamycin
[35]. Thus, the major concern for the phenotype signature is class characterization rather
than prediction of clinical outcomes. Proper classification with well-defined phenotype
signatures and linking them with functional and clinical utilities such as chemical or drug
responses would be a promising strategy to develop novel cancer treatment modality for a
certain tumor subtype, opening new era of personalized medicine [42,43].
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The gene signatures representing distinct cellular processes or molecular pathways are
referred as function signature. For example, the target gene signatures for MET [44], TGFB
[45], MYC [46], and RB [47] have been identified from knock-out or transgenic animal
models. As an application of function signatures, comparative analysis using different
mouse models has demonstrated that the MYC-TGFA transgenics had similar expression
patterns with HCCs of the poorer survival group, suggesting the regulatory role of TGFA
signaling in aggressive progression of HCC [48]. In addition to such experimental models,
computationally predicted or manually curated databases can be categorized as function
signatures such as Gene Ontology (http://www.geneontology.org), microRNA targets (e.g.,
MirBase, http://microrna.sanger.ac.uk, or TargetScan, http://www.targetscan.org), protein–
protein interactions (e.g., IntAct, http://www.ebi. ac.uk/intact), or transcription factor-
binding (e.g., TRASNFAC, http://www.biobase-international.com).
As like phenotype signature, function signatures can represent phenotypes, but they have
more causal or functional relevance. Thus, they are useful in functional interpretation of
tumor classification. However, since gene expression profile is only a “snap-shot” of gene-
to-gene interaction, they inevitably include many of nonspecific “by-stander” genes which
are not functionally associated. Therefore, functional roles of the genes in function signature
need to be addressed more carefully in detail. Particularly, proliferation- or cell cycle-related
genes can easily be co-founded as by-stander genes, because the expression of these genes
might be altered as an end result of disease progression. With this concern, a previous study
has tested the possible effect of those genes by simply subtracting them from embryonic
stem (ES) cell signatures [49]. This would be one of solutions for the signature purification
to remove unwanted effects of the by-stander genes, although further accurate solutions
might be required.
The pathogenesis of HCC is thought to be processed by multi-step pathologic states of
chronic cirrhotic lesions, dysplastic nodules, and progression to early and advanced HCC
[3,4]. The function signatures as well as phenotype signatures could address key regulators
and genetic events during step-by-step progression of tumors (Figure 2). In earlier study,
Nam et al. [31] have shown the discrete expression patterns (i.e., phenotype signature)
across the multi-step hepatocarcinogenesis from low- to high-grade dysplastic nodules and
HCCs. In addition, by performing pathway analysis, Wurmbach et al. [32] have further
revealed the dysregulation of the Notch and Toll-like receptor pathways in cirrhosis,
followed by dysregulation of Jak/STAT in early carcinogenesis. The application of MYC
signature has also revealed its regulatory role during malignant conversion from dysplasia to
early HCC [46].
Besides these findings, genetic events such as gene mutation (e.g., TP53, CTNNB1, and
KRAS), DNA methylation [50], and other gene expressions (e.g., IGF, VEGFR, CD24) have
been noticed to involve the multi-step hepatocarcinogenesis, and their targeted therapies are
now under investigation [51]. Signaling pathways such as proliferation (e.g., TGFA, EGF,
IGF2, and HGF), differentiation (e.g., Wnt and TGFB), inflammation (e.g., IL6, IFN, and
TNFA), and angiogenesis (e.g., VEGF, FGF, PDGF, and angiopoietin) were frequently
deregulated resulting in high complexity and heterogeneity of HCC [see details in review
[52,53]]. Such multiple and multistep complexity of genetic interaction impedes complete
understanding of the genetic pathogenesis of hepatocarcinogenesis. Further extended studies
defining phenotype or function signatures with multi-layered platform data including
microRNAs, DNA copy numbers, or epigenetic changes are required to further delineate the
multi-step hepato-carcinogenesis.
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In cancer genomics studies, many of researchers are now interested in identifying molecular
determinants of disease pathogenesis and novel therapeutic targets. These could be
identified from prediction, function, or phenotype signatures. However, since lengthy gene
list of those signatures would preclude the further evaluation of target genes, it would be
important to select the most promising candidates as minimum as possible. To prioritize the
most probable candidate genes, systemic integration of the gene signatures from multiple
layers of data sets is thought to be “state-of-art” strategy. Data integration with multiple-
layered platforms may have advantage to overcome the limitation of each platform data by
reducing biased observation in each data set. For example, recent integrative analysis of
microRNA target signatures from different databases could successfully identify novel
oncogenic function of mir-101 in prostate cancer [54]. In HCC, cross-species comparative
analysis of array-based comparative genomic hybridization (CGH) has revealed novel
cancer genes, cIAP1 and Yap [55]. The same group also performed an efficient high-
throughput screening of siRNA libraries by analyzing array CGH data, which discovered 13
novel tumor suppressor genes including XPO4 [56]. In addition, we have shown a successful
integration of array CGH and gene expression profiling data [57]. Guiding the gene
selection strategy by assessing the prognostic impact of the selected genes, we identified 50
potential driver genes including NCSTN and SCRIB. Then, further interrogation of the
driver genes by using Connectivity Map database [58] could identify molecular targets (i.e.,
EGFR, mTOR, and AMPK) of the driver genes suggesting their mechanistic implications.
These studies of systematic and integrative analyses of genomic profiles to select candidate
target genes can speed up the screening and validation process of cancer-gene discovery and
therapeutic targets.
INTEGRATIVE ANALYSIS UNVEILS COMPLEXITY
As shown in previous studies, appropriate integration of independent genomic data had a
great advantage to identify novel molecular targets. Huge data repositories of microarray
data, Gene Expression Omnibus (GEO) [59] and ArrayExpress [60] has enabled the
researchers to perform integrative data analysis. In addition, as one of pioneering resources
for integrative genomic profiling, National Cancer Institute 60 (NCI60) cell line panel has
been established [61]. NCI60 had multi-dimensional data sets for 60 cancer cell lines
including profiles of mRNAs, proteins, microRNAs, DNA copy numbers, gene mutations,
and drug responses. These multilayered data integration could unveil molecular complexity
by linking phenotypes and gene expression signatures [61–63]. Similar approaches for the
cell-line based screen of candidate drugs have shown an efficient improvement of the
evaluation process for anti-cancer agents [see review in [64]]. In addition, recent
developments of huge data repositories such as The Cancer Genome Atlas (TCGA) [65],
Connectivity Map, and Oncomine [66] will also be useful resources for integrative analysis
of cancer genome, providing more qualified molecular targets [67,68].
Interaction of signatures is one of the challenging issues in the future integrative analyses.
Recently, Chinnaiyan’s group has succeeded integrative data analyses using the gene
signatures from multidimensional data sets. They developed a newer technique, “molecular
concept map” (MCM) to address higher-level patterns across multiple and disparate
microarray experiments [69]. Differing from the previous studies linking one-to-one or one-
to-many association between signatures and phenotypes, MCM has linked many-to-many
association among function and phenotype signatures by integrating different data types of
pathways, proteins, and networks in an unbiased approach. The same group also developed
an algorithm, that is, Cancer Outlier Profile Analysis (COPA) [70]. By identifying outlier
expression across cancer samples, it could successfully reveal novel and uncharacterized
oncogenic alterations. In another study, network analysis by constructing a BRCA-centered
Woo et al. Page 5




network (BCN) could identify novel susceptibility genes in breast cancer [71]. Such
attempts on higher-level systematic approaches by integrating multiple and multi-level data
resources would be promising to delineate genomic determinants in cancer development and
progression (summarized in Figure 3); however, only a few of such integrative approaches
have been applied to liver cancers.
CONCLUSION
We have reviewed the current status of the HCC gene expression profiling studies
particularly the signature outcomes. Our classification of gene expression signatures as
prediction, phenotype, function, and molecular targets would be helpful to address the
distinction and the current trends of the application of genomic data to cancer research.
The accumulation of genome-wide “omics” data has provided us new opportunities to
understand disease mechanisms at systems level. Moreover, emerging new technologies
such as massively parallel sequencing and their applications (e.g., RNA-seq and ChiP-Seq)
enabled researchers to investigate new parameters, such as mutations, alternative splicing,
epigenetic silencing, and DNA-protein interactions which have not been resolved by current
microarray technologies [72–74]. However, as data become complex and the study purposes
are diverse, more careful attention on appropriate study design, reporting, and analytical
strategies become essential in genomics studies. We believe that the systems view of cancers
by constructing integrative atlas of genomic profiles with appropriate study design and
analysis strategies would provide great potential for improving cancer management as well
as understanding the cancer pathobiology.
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Postulated diagram of the cellular origin of HCC. The postulated cellular origins of HCC
based on the expression status of cholangiocarcinoma (CC), embryonic stem (ES) cell, and
hepatoblast (HB) signatures were illustrated. Details for cellular origin of CC were
omitted. + The expression of cellular origin signatures. CHC represents combined
hepatocellular cholangiocarcinoma. Reprinted from Ref. [41].
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Genetic aberrations during multi-step hepatocarcinogenesis identified by genome-wide high-
throughput profiling studies.
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Strategies and resources for integrative analysis of genomic profiling data. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Table 1
Classification of Gene Signatures Identified by Gene Expression Profiling
Category Description Clinical correlations External validation methoda
Prediction signature: predict clinical outcomes
 Iizuka et al.
[12]
Predict early recurrence by 12 gene signature Recurrence Same platform
 Ye et al. [13] Predict metastasis in HBV-related HCC Metastasis Same platform
 Lee et al. [14] Predict survival by 406 gene signature Survival Same platform
 Budhu et al.
[15]
Predict metastasis by stromal tissue signature Metastasis, survival Same platform
 Wang et al. [16] Predict recurrence by 57 gene signature Recurrence Same platform
 Woo et al. [17] Predict early recurrence in HBV-related HCC
CD24 was identified as biomarker for early
recurrence
Recurrence Cross platform
 Hoshida et al.
[18]
Predict late recurrence using formalin-fixed,
paraffin-embedded (FFPE) stromal tissues
Recurrence Same platform
 Budhu et al.
[19]
Predict metastasis by microRNA signature Metastasis, survival Same platform
 Ji et al. [20] Identify mir-26 as predictor for survival and




 Poon et al. [21] Predict survival by DNA copy numbers Survival Not determined
 Hernandez-
Vargas et al. [22]
Predict survival by 58 DNA methylation Survival Not determined
Phenotype signature: define characteristics of cancer subtype
 Nam et al. [31] Identify classifiers for low-to high-grade
dysplasia and HCCs
Not determined Not determined
 Wurmbach et
al. [32]
Identify dysregulated pathways for 4 neoplastic
stages of HCV-related HCC
Not determined Not determined
 Ura et al. [33] Identify a microRNA signature which is
differentially expressed between HBV- and
HCV-related HCC
Not determined siRNA-mediated silencing
 Chiang et al.
[34]
Classify phenotypes of proliferation, CTNNB1,
IFN-related, polysomy 7, and unannotated
Recurrence Not determined
 Katoh et al. [35] Identify subclasses, e.g., c-Myc-induced HCC,
6p/1q-amplified HCC, and 17q-amplified HCC
Survival Rapamycin sensitivity in 17q gained
tumor cell lines
 Boyault et al.
[36]
Identify 6 classes based on gene expression,
mutation, methylation, and LOH
Survival Not determined
 Lee et al. [37] Identify hepatoblast-like class Survival, recurrence Same platform
 Yamashita et al.
[38]
Identify progenitor-like class using EpCAM and
AFP
Survival Same platform, immunohistochemistry
 Andersen et al.
[39]
Identify progenitor-like class using CK19
expression
Survival, recurrence Not determined
 Cairo et al. [40] Identify child hepatoblastoma-derived signature Survival qPCR
 Woo et al. [41] Identify cholangiocarcinoma-like class Survival, recurrence Cross-platform
Function signature: functionally related gene sets (pathways)
 Kaposi-Novak
et al. [44]
Met knock-out signature Survival Cross platform
 Coulouarn et al.
[45]
TGF-β knock-out signature Survival Cross platform
 Kaposi-Novak
et al. [46]
Myc signature expression during malignant
conversion
Not determined Cross platform
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Category Description Clinical correlations External validation methoda
 Mayhew et al.
[47]
RB knock-out signature Survival Not determined
 Lee et al. [48] Signatures from mouse transgenics of E2F,
MYC, MYC-E2F1, and MYC-TGFA
Survival group Not determined
Molecular target signature: candidate gene sets for molecular therapies
 Zender et al.
[55]
cIAP1 and Yap are identified in DNA amplicons Not determined In vivo overexpression
 Zender et al.
[56]
13 genes including XPO4 are identified by
shRNA screening of the overlapped deleted
genomic regions in human and mouse tumors
Not determined shRNA-mediated silencing
 Woo et al. [57] 50 potential driver genes are identified by




Functional validations by experiments and external validations using independent data sets were considered.
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